Trial Search Results
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
This is an open-label, non-randomized, interventional, single group assignment study of omidubicel in patients with hematologicalmalignancies for whom allogeneic stem cell transplant (SCT) is currently a recommended and potentially lifesaving treatment, allwith required disease features rendering them eligible for allogeneic transplantation.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Gamida Cell ltd
Stanford Investigator(s):
Intervention(s):
- Biological: omidubicel
Phase:
Phase 3
Eligibility
Inclusion Criteria:
- Patients must be at least 12 years of age
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Sufficient physiological reserves
- Females of childbearing potential agree to use appropriate method of contraception
- Signed written informed consent
Exclusion Criteria:
- Extensive bone marrow fibrosis
- Donor specific anti-HLA antibodies
- Pregnancy
- Medically unsuitable for transplant
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Khanh Nguyen
650-721-2372
Recruiting